Redeye concludes that Q2 was stronger than Redeye expected, with higher-than-expected revenues and l...
Redeye comments on Starbreeze strong Q2 report. Net sales of SEK43.
Redeye comments on Fragbite Groups Q2’23 report, which showed a bit lower sales and profitability le...
Redeye gives an initial take on Binero’s H1 2023 report, being the first time the company provides h...
Marimekko reported Q2 results above expectations. Q2 net sales came in line with our estimates while...
Redeye states that while Q2 was soft, it was due to a timing effect implying that Q3 will be strong.
Q2 revenues 2% below ABGSCe, EBIT 9% below Signs of improving paper demand positive, but not surpris...
Q2e: -2% organic growth, EBITA SEK 94m (-16% y-o-y) Keeping FY guidance should be supportive for est...
Redeye comments on Sozap’s Q2 results, which were somewhat better than expected.
Redeye endorses yesterday's news that Sprint Bioscience has licensed the global rights to its cancer...
Vow will report its Q2 2023 results on 23 August. We pencil in sales of NOK 435m (up 14% from H2 202...
Agilyx is reporting its H1 2023 results on 22 August, for which we pencil in revenue of USD 9m (18% ...
Carlsquare Equity Research has published a research update following the Q2 2023 report.
I dag offentliggjorde Midsummer sin delårsrapport för det andra kvartalet 2023.
Revenue back on track, better margins from the next quarter Programme end-of-life announcement for H...
Movinn announced on August 14th, that the company (as operator and tenant) has signed a long-term le...
Margin pressure to persist but fade in coming quarters We cut EBITA by 16%, 8%, and 7% for '23e-'25e...
Redeye updates its estimates and fair value range after Physitrack’s stable Q2 2023 report, which ca...
Redeye comments on the wholesale distributor agreement in the US with VHSS.
Q2 adj. EBITDA 6% above our estimates New '23 guidance, EUR 125-130m top line & 47-50% margin Share ...
